Perfuze completed the MARRS study, which earned Millipede88 its FDA thrombectomy label, with primary endpoint met.
Public source
Publisher name
Public post
Proud milestone for the Perfuze team. MARRS is the pivotal study that earned Millipede88 its FDA thrombectomy label - independently adjudicated, primary endpoint met. 75…
Company
Perfuze
Neurovascular medical device company developing technology for Ischemic Stroke
- Industry
- Medical Equipment Manufacturing
- Location
- Galway, IE
- Company size
- 51–200 employees
About Perfuze
Perfuze, a Galway-based medical device company, is advancing fast, safe, and predictable stroke treatment through innovation. Backed by the MARRS trial clinical evidence, the Millipede™ System’s unique corrugated design offers best-in-class deliverability and precise vessel matching for superior first-pass success. Combining powerful aspiration with reliable performance, the Perfuze portfolio helps physicians restore blood flow quickly and safely.
See moreLatest activity
Latest activity from Perfuze
3 signals
Research & Knowledge
Perfuze achieved first-pass reperfusion success that lifted 90-day functional independence for patients by 17 points, with 60.6% vs. 43.4% compared to Millipede88 delivering first-pass success in 75% of M1 MCA strokes.
Legal & Regulatory
Perfuze announced that the independently adjudicated MARRS study met its primary endpoint and supported FDA clearance of the Millipede88 Super-Bore Catheter for direct aspiration.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Solaris Endovascular
Solaris Endovascular announced 92.7% target lesion primary patency at six months with investigational Solaris DE in the DEScover Phase II study presented at CIRSE 2026.
Research & Knowledge
iVascular
iVascular presented the 1-year outcomes of the iliCo study at CIRSE 2026, showing strong results for iCover in aortoiliac occlusive disease with 96.7% fTLR and patient clinical improvement of 90.4%
Research & Knowledge
Argon Medical Devices, Inc.
Argon Medical Devices, Inc. published outcomes from 110 patients treated across interventional radiology and vascular care settings using the CLEANER Vac Thrombectomy System.
Research & Knowledge
Shockwave Medical
Shockwave Medical published a Vascular News supplement examining the evolving role of Shockwave IVL in the treatment of complex calcified lesions, highlighting calcium modification and endovascular intervention in peripheral lesions.
Research & Knowledge
Cagent Vascular